Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Busse

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Journal of Clinical Psychopharmacology|June 28, 2021
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Clinical Therapeutics|July 30, 2020
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age ChildrenAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Ecology|February 25, 2016
Aboveground vertebrate and invertebrate herbivore impact on net N mineralization in subalpine grasslandsAnita C Risch, Martin Schotz, Martijn L Vandegehuchte, et al.
Nature Communications|September 13, 2018
Size-dependent loss of aboveground animals differentially affects grassland ecosystem coupling and functionsA C Risch, R Ochoa-Hueso, W H van der Putten, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Journal of Clinical Psychopharmacology|June 28, 2021
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Clinical Therapeutics|July 30, 2020
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age ChildrenAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Ecology|February 25, 2016
Aboveground vertebrate and invertebrate herbivore impact on net N mineralization in subalpine grasslandsAnita C Risch, Martin Schotz, Martijn L Vandegehuchte, et al.
Nature Communications|September 13, 2018
Size-dependent loss of aboveground animals differentially affects grassland ecosystem coupling and functionsA C Risch, R Ochoa-Hueso, W H van der Putten, et al.
Pageof 7